Pharvaris (PHVS) Leases (2025 - 2026)
Pharvaris posted quarterly Leases of $836078.6 for Q1 2026, down 5.11% on a QoQ basis from $881123.9 in Q4 2025.
Pharvaris (PHVS) has 2 years of Leases data on file, last reported at $836078.6 in Q1 2026.
- For the quarter ending Q1 2026, Leases changed N/A year-over-year to $836078.6; the trailing twelve-month figure through Mar 2026 stood at $836078.6 (changed N/A YoY), and the FY2025 full-year result was $855211.7, changed N/A from the prior year.
- Leases for Q1 2026 stood at $836078.6, down from $881123.9 in the prior quarter.
- Across five years, Leases topped out at $881123.9 in Q4 2025 and bottomed at $836078.6 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 61,822.50 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 189.30 Mn |
| 10 | Pharvaris | 267.74 Mn | -73.74 Mn | - | 836,078.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 836,078.64 |
| Dec 31, 2025 | 881,123.90 |